Financial Performance - The annual operating revenue reached approximately RMB 263.1 million, a decrease of about 9.0% compared to the previous year[16] - The annual loss amounted to approximately RMB 56.9 million, compared to a loss of RMB 19.2 million in the previous year[16] - The company's operating revenue for the year was approximately RMB 263.1 million, a decrease of about 9.0% compared to RMB 289.1 million in the previous year[34] - Gross profit for the year was approximately RMB 108.4 million, down about 14.9% from RMB 127.4 million last year, resulting in a gross margin of approximately 41.2% compared to 44.1% in the previous year[35] - The company reported a net loss of approximately RMB 56.9 million for the year, compared to a loss of approximately RMB 19.2 million in the previous year, primarily due to declines in operating revenue and gross profit[41] - Basic and diluted loss per share for the year was RMB (0.294), compared to RMB (0.080) in the previous year, reflecting a worsening financial position[198] - Financial asset impairment losses increased to RMB 6,528,000 from RMB 712,000 in 2023, highlighting growing concerns over asset quality[198] Dividend Policy - The company did not recommend the distribution of any dividends for the fiscal year ending December 31, 2024, consistent with the previous year[19] - The group reported no dividends for the fiscal year ending December 31, 2024, consistent with the previous year[121] - As of December 31, 2024, the company recorded a cumulative loss of approximately RMB 53,196,000, with no distributable reserves available for shareholders, compared to approximately RMB 14,433,000 as of December 31, 2023[129] Market Environment - The IVD industry experienced significant changes, with the end of COVID-19 testing and a shift in the market landscape, leading to a decline in product sales prices[20] - Despite challenges, the demand for disease testing is increasing due to an aging population and rising chronic disease rates, supported by increased government investment in health[20] - The ongoing tightening of cost control policies under the national medical insurance system has further compressed the company's profit margins[20] - The company faced a 30%-40% average price drop in key biochemical diagnostic reagent products due to centralized procurement, impacting overall revenue[28] - The demand for chronic disease diagnostic IVD products is increasing due to an aging population, although the company needs to enhance market promotion and product innovation to keep pace[29] Research and Development - R&D investment for the year was approximately RMB 33.4 million, with several new diagnostic systems and products approved for market, including nine newly registered products[26] - Research and development expenses totaled approximately RMB 33.4 million, a decrease of about 6.7% from RMB 35.8 million in the previous year[38] - The company is committed to increasing R&D investment and accelerating the development of new products, particularly in chemiluminescence reagents and molecular diagnostics[45] - The company is focused on enhancing its research and development capabilities to mitigate risks associated with technological obsolescence in the IVD industry[100] Strategic Initiatives - The company is exploring new opportunities for growth amid the crisis, driven by technological innovation in the IVD sector[20] - The company plans to strengthen collaborations with research institutions and universities to boost innovation capabilities and attract talent[22] - The company is actively expanding its market channels both domestically and internationally, with a focus on Southeast Asia, where it has successfully entered the market with biochemical diagnostic reagent products[33] - The company aims to strengthen customer relationships by providing personalized solutions and one-stop services, enhancing customer satisfaction and product stickiness[33] - The company has a strategic plan to explore potential mergers and acquisitions to strengthen its market position and product offerings[167] Corporate Governance - The board of directors is responsible for overseeing the company's management, business strategy, and financial performance[60] - The board held five meetings in 2024 with an average attendance rate of 96%[66] - The company has established mechanisms to ensure independent opinions from non-executive directors, including annual reviews of their contributions[62] - The company has adopted a standard code for securities trading by directors, ensuring compliance with GEM Listing Rules[69] - The company has maintained a robust corporate governance system, adhering to all code provisions except for the internal audit function, which is currently not established due to the group's scale and operational structure[148] Risk Management - The company has established a comprehensive risk management system to identify and manage key operational risks[99] - The board regularly reviews the effectiveness of internal controls and risk management systems to protect the interests of the company and its shareholders[97] - The company has implemented measures to manage accounts receivable effectively, reducing the risk of bad debts as sales scale increases[102] - The company has established an emergency mechanism to respond to natural disasters and public health events, ensuring rapid response capabilities[102] Employee and Talent Management - The total employee cost for the year was approximately RMB 103 million, up from RMB 99 million in 2023[53] - The company employed a total of 499 full-time employees as of December 31, 2024, down from 537 in 2023[53] - The company is committed to attracting and retaining high-quality talent to maintain its competitive advantage in the IVD industry[101] - The company will continue to focus on training and long-term development opportunities for female employees[81] Financial Compliance - The board confirmed compliance with all relevant laws and regulations that significantly impact the group's business and operations during the year[130] - The company has implemented measures to ensure compliance with the GEM Listing Rules and relevant laws and regulations[57] - The independent non-executive directors confirmed their independence as per the GEM Listing Rules[134]

Financial Performance - For the fiscal year ending December 31, 2024, the company reported total revenue of RMB 263,069,000, a decrease of 9.0% from RMB 289,073,000 in the previous year[4]. - The gross profit for the same period was RMB 108,400,000, down 14.9% from RMB 127,365,000 in 2023[4]. - The company incurred a net loss of RMB 56,889,000, compared to a net loss of RMB 19,241,000 in the prior year, representing an increase in losses of 195.5%[5]. - Basic and diluted loss per share for the year was RMB 0.294, compared to RMB 0.080 in the previous year[4]. - The company's operating revenue for the year was approximately RMB 263.1 million, a decrease of about 9.0% compared to RMB 289.1 million in the previous year[54]. - Gross profit for the year was approximately RMB 108.4 million, down about 14.9% from RMB 127.4 million in the previous year, with a gross margin of approximately 41.2% compared to 44.1% in the previous year[55]. - The company reported a loss attributable to equity holders of the parent of RMB 42,532 thousand in 2024, compared to a loss of RMB 11,648 thousand in 2023, indicating a significant increase in losses[38]. Assets and Liabilities - Total assets decreased to RMB 477,372,000 from RMB 563,515,000, reflecting a decline of 15.3%[6]. - Current liabilities exceeded current assets by approximately RMB 7,490,000 as of December 31, 2024[13]. - The group's cash and cash equivalents amounted to approximately RMB 68,213,000, while total bank borrowings were approximately RMB 143,665,000[13]. - The net current liabilities as of December 31, 2024, were approximately RMB 7,490,000, compared to RMB 29,393,000 in 2023, indicating a significant improvement in liquidity[42]. - Trade receivables decreased from RMB 183,300 thousand in 2023 to RMB 127,845 thousand in 2024, a reduction of approximately 30.2%[39]. - Trade payables decreased from RMB 111,540 thousand in 2023 to RMB 87,108 thousand in 2024, a decrease of approximately 22%[41]. Cash Flow and Financing - The company's cash and cash equivalents increased to RMB 68,213,000 from RMB 63,410,000, showing a growth of 12.7%[6]. - The group has secured bank financing approval of approximately RMB 100,000,000, which can be drawn as needed[13]. - The group has approximately RMB 20,000,000 of undrawn bank financing available for additional loans[13]. - The net debt rose to RMB 80,008,000 in 2024, compared to RMB 79,307,000 in 2023, indicating a slight increase of about 0.9%[66]. - The capital debt ratio increased to 46% in 2024 from 34% in 2023, showing a significant rise of 35.3%[66]. Research and Development - Research and development expenses were RMB 33,418,000, slightly down from RMB 35,806,000, indicating a reduction of 6.7%[4]. - The company's R&D investment for the year was approximately RMB 33.4 million, with several new diagnostic systems and products approved for market[46]. - The company aims to enhance its product pipeline by focusing on flow cytometry instruments and reagents, chemiluminescence instruments and reagents, and molecular diagnostic products, with several projects currently in clinical trial stages[51]. - The company has registered or applied for registration of 9 new products, including the adiponectin assay kit, indicating ongoing innovation in product offerings[46]. Market and Competition - Approximately 91% of the group's revenue for the year came from customers located in mainland China[20]. - The IVD industry is experiencing intensified competition, with both domestic and international players vying for market share, complicating market expansion efforts for the company[48]. - The company plans to strengthen its market presence in the grassroots healthcare sector, leveraging its product cost-performance advantages and localized service capabilities[63]. - The company aims to expand its international market presence, particularly in Southeast Asia, Africa, and Latin America, to increase product recognition and market share[65]. Corporate Governance - The company has complied with all applicable code provisions of the Corporate Governance Code, except for the establishment of an internal audit function[88]. - The audit committee, consisting of four independent non-executive directors, has reviewed the audited consolidated results and internal control systems[86]. - The company announced that it failed to comply with the GEM Listing Rules regarding related party transactions, with total sales of reagent products and procurement of testing reagents and consumables amounting to approximately RMB 16.99 million (approximately HKD 18.69 million) for the year ended December 31, 2022[89]. Employee and Operational Efficiency - Employee benefits expenses rose to RMB 102,930 thousand in 2024, up from RMB 99,218 thousand in 2023, an increase of 2.7%[27]. - The total employee cost for the year was approximately RMB 103,000,000, up from RMB 99,000,000 in the previous year, representing an increase of about 4.0%[73]. - The company employed a total of 499 full-time employees as of December 31, 2024, down from 537 in 2023, indicating a reduction in workforce[73]. - The company is actively pursuing strategic mergers and acquisitions to optimize resource allocation and enhance overall strength in response to industry consolidation trends[63]. - The company will continue to optimize internal management processes and improve operational efficiency while controlling costs[65].

中 生 北 控 生 物 科 技 股 份 有 限 公 司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION 2024 中期報告 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供一個上市 的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後 方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專業及其他老練投資者。 由於GEM 上市公司新興的性質所然，在GEM 買賣的證券可能會較於聯交所主板買賣之證 券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 本報告乃遵照GEM《證券上市規則》（「《GEM上市規則》」）的規定提供有關中生北控生物 科技股份有限公司（「本公司」，與其附屬公司統稱為「本集團」）的資料，本公司各董事（「董 事」）願就本報告共同 ...

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of RMB 133,828,000, a decrease of 3% from RMB 139,146,000 in the same period of 2023[2] - The gross profit for the same period was RMB 58,531,000, down 12% from RMB 66,676,000 year-on-year[2] - Operating loss increased to RMB 11,951,000 compared to a loss of RMB 5,490,000 in the prior year[2] - The net loss for the period was RMB 18,314,000, which is a significant increase from RMB 8,011,000 in the previous year[2] - Basic and diluted loss per share was RMB 0.091, compared to RMB 0.037 in the same period last year[2] - The total comprehensive loss for the six months ended June 30, 2024, was RMB (18,337,000), compared to RMB (7,956,000) for the same period in 2023, reflecting an increase in losses[6] - The company reported a loss of approximately RMB 18.3 million for the reporting period, compared to a loss of RMB 8 million in the same period last year[37] Assets and Liabilities - Total assets as of June 30, 2024, were RMB 538,339,000, a slight decrease from RMB 563,151,000 as of December 31, 2023[4] - Current liabilities totaled RMB 311,085,000, down from RMB 320,747,000 at the end of 2023[5] - The company’s cash and cash equivalents decreased to RMB 35,076,000 from RMB 63,410,000 at the end of the previous year[4] - Non-current assets amounted to RMB 212,552,000, slightly down from RMB 213,111,000 at the end of 2023[4] - The company reported a total equity of RMB 213,067,000, down from RMB 231,404,000 at the end of the previous year[5] - Trade receivables at the end of the reporting period amounted to RMB 177,518,000, a decrease from RMB 179,798,000 at the end of 2023[21] - Trade payables at the end of the reporting period were RMB 108,517,000, down from RMB 111,540,000 at the end of 2023[22] - The company’s bank loans totaled RMB 141,312,000, a slight decrease from RMB 142,717,000 in the previous year[23] - The company has a guarantee of RMB 6,000,000 for a loan granted to a subsidiary, down from RMB 10,000,000 at the end of 2023[25] Cash Flow - The net cash flow used in operating activities for the six months ended June 30, 2024, was RMB (28,956,000), compared to RMB (21,278,000) for the same period in 2023, indicating a worsening cash flow situation[7] - The company reported a net cash outflow from investing activities of RMB (927,000) for the six months ended June 30, 2024, compared to RMB (2,663,000) in the same period of 2023[7] - The company's cash and bank balances decreased to RMB 35.1 million from RMB 63.4 million as of December 31, 2023[40] Expenses - The cost of goods sold and services provided for the six months ended June 30, 2024, was RMB 75,297,000, an increase from RMB 72,470,000 in the same period of 2023[15] - Total expenses for the period were RMB 2,212,000, compared to RMB 1,841,000 for the same period in 2023, representing an increase of approximately 20.2%[18] - The total tax expense for the period was RMB 2,169,000, slightly down from RMB 2,201,000 in the previous year[18] Employee and Workforce - As of June 30, 2024, the total employee cost for the group was approximately RMB 52.1 million, an increase from RMB 47.7 million in the same period last year, reflecting a growth of 7%[47] - The group employed a total of 554 full-time employees as of June 30, 2024, compared to 530 employees a year earlier, indicating a growth in workforce of approximately 4.5%[47] - The company emphasizes the importance of employee training and regularly reviews its compensation policies to maintain competitive salary levels[47] - The board believes that employees are one of the company's most important assets, contributing significantly to its success[47] Research and Development - Research and development expenses increased to approximately RMB 16.9 million, a rise of about 5.6% from RMB 16 million in the same period last year, with 50 Class II products registered and 9 new products under development[36] Corporate Governance - An audit committee has been established to review and supervise the company's financial reporting procedures and internal control systems, consisting of four independent non-executive directors[56] - The company has applied the principles and applicable code provisions of the Corporate Governance Code during the reporting period, with regular reviews of governance policies[57] - The company did not comply with certain provisions of the GEM Listing Rules regarding internal audit functions due to its operational scale and structure, but has implemented sufficient measures for risk management and internal control[58] Shareholder Information - The largest shareholder, Beijing Pusai Asset Management Co., Ltd., holds 31,308,576 shares, representing 38.93% of the company's domestic shares and 21.64% of the total registered capital[50] - Chen Peng, a director, holds 11,330,334 shares, accounting for 14.09% of the company's domestic shares and 7.83% of the total registered capital[50] - Chen Zhengyong, another director, owns 10,000,000 shares, which is 12.43% of the domestic shares and 6.91% of the total registered capital[50] Compliance and Regulatory Matters - The company announced non-compliance with the GEM Listing Rules related to transactions with Anhui Guoke Kangyi Medical Technology Co., Ltd., involving total amounts of approximately RMB 16.99 million, RMB 5.05 million, and RMB 1.61 million for respective periods[59] - The board is unaware of any information that needs to be disclosed under the GEM Listing Rules after reasonable inquiries during the reporting period[60]

中 生 北 控 生 物 科 技 股 份 有 限 公 司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION 2023 年 報 Annual Report 2023 中 生 北 控 生 物 科 技 股 份 有 限 公 司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION (Incorporated in the People's Republic of China with limited liability) (Stock Code : 8247) Annual Report ���� 年報 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供一個上市的市場。有意投資的人士應了解 投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。GEM 的較高風險及其他特色表示GEM 較適合 專業及其他老練投資者。 由於GEM 上市公司新興的性質所然，在GEM 買賣的證券可能會較於聯交所主板買賣之證券承受較大的市場波動風險，同 時無法保證在GE ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不會就本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 截至二零二三年十二月三十一日止年度的全年業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM 的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交 所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在 風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM 上市公司普遍為中小型公司，在GEM 買賣的證券可能會較於主板買賣 之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量 的市場。 香港交易及結算所有限公司及聯交所對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不會就本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告乃遵照聯交所GEM證券上市規則（「GEM上市規則」）的規定提供有關中生 北控生物科技股份有限公司（「本公司」）的資料，本公司各董事（「董事」）願就本 公告共同及 ...

Financial Performance - For the three months ended September 30, 2023, the company reported revenue of RMB 71,418,000, a decrease of 30.8% compared to RMB 103,223,000 for the same period in 2022[14] - The gross profit for the third quarter of 2023 was RMB 35,217,000, down 23.1% from RMB 45,757,000 in the third quarter of 2022[14] - The operating loss for the third quarter of 2023 was RMB 6,255,000, compared to an operating profit of RMB 12,472,000 in the same quarter of the previous year[14] - The net loss attributable to the owners of the parent company for the third quarter of 2023 was RMB 569,000, compared to a profit of RMB 10,691,000 in the third quarter of 2022[14] - The company reported a net loss of RMB 10,698,000 for the nine months ended September 30, 2023, compared to a profit of RMB 17,377,000 for the same period in 2022[14] - The total revenue for the nine months ended September 30, 2023, was RMB 210,564,000, a decrease of 23.6% from RMB 275,659,000 in the same period of 2022[14] - The company’s total comprehensive loss for the nine months ended September 30, 2023, was RMB 10,662,000, compared to a profit of RMB 17,412,000 in the same period of 2022[15] - The company’s basic and diluted loss per share for the third quarter of 2023 was RMB 0.004, compared to earnings per share of RMB 0.074 in the same quarter of 2022[14] - The company reported a basic loss per share attributable to shareholders of RMB 4.86 for the three months ended September 30, 2023, compared to earnings of RMB 73.93 per share in the same period of 2022[26] Research and Development - Research and development expenses increased to RMB 9,724,000 in the third quarter of 2023, up 46.5% from RMB 6,646,000 in the same quarter of 2022[14] - The company continues to focus on expanding its research and development efforts despite the financial losses reported[14] - The company successfully obtained certification for over 50 core innovative products, including first and second-generation flow cytometers, from the Anhui Provincial Drug Administration, pushing them into clinical and research markets[31] - The company is focused on accelerating the transformation of scientific research achievements and improving its product pipeline through the establishment of a technology achievement transformation center[35] Market and Business Strategy - In the first three quarters of 2023, the company faced a gradual recovery in domestic medical institution visits and a steady growth in routine in vitro diagnostic testing demand[31] - The company aims to leverage the good opportunity of multi-province centralized procurement of biochemical reagents to further expand the market and improve cost efficiency[35] - The company is actively building a chain of precision medicine laboratories in cities like Beijing, Hefei, Chengdu, Jinan, and Nanchang to enhance research collaboration and academic promotion[31] - The company plans to strengthen its competitive advantage in the biochemical diagnostic market and increase market share through various initiatives[35] - The strategic cooperation system with institutions like the Chinese Academy of Sciences and major hospitals is expected to drive business development through integrated industry-university-research collaboration[35] - The company has received positive market feedback for its innovative equipment and reagent products in biochemistry, immunology, and early cancer screening[31] Ownership and Governance - The company reported a significant ownership structure, with key stakeholders holding approximately 36.01% each in Hong Kong Zhixin Investment Limited[1] - Yunnan Shengneng Investment Partnership holds a 43.0% stake, indicating a diversified ownership among multiple shareholders[2] - The company has established an audit committee to oversee financial reporting and internal control systems, ensuring compliance with GEM listing rules[3] - The company has adhered to all provisions of the Corporate Governance Code as per GEM listing rules, with minor exceptions noted[5] - The board has implemented measures to maintain risk management and internal control without establishing a dedicated internal audit department[6] - The company is committed to reviewing the necessity of an internal audit function periodically, based on operational needs[7] - The management team has engaged external consultants for internal reviews, enhancing oversight and compliance[8] - The company has not disclosed any conflicts of interest among its directors and management during the reporting period[9] - No significant changes in shareholder equity or related interests were reported as of September 30, 2023[10] Other Financial Information - The company’s financial expenses for the third quarter of 2023 were RMB 1,844,000, slightly up from RMB 1,843,000 in the same quarter of 2022[14] - The company did not declare an interim dividend for the nine months ended September 30, 2023, consistent with the previous year[30] - The company’s rental income for the three months ended September 30, 2023, was RMB 403,000, a decrease of 96.9% from RMB 13,345,000 in the same period of 2022[21] - The company’s deferred tax expense for the nine months ended September 30, 2023, was RMB 342,000, compared to RMB 2,000 in the same period of 2022[25] - The company’s total reserves as of September 30, 2023, amounted to RMB 199,892,000, down from RMB 210,451,000 as of September 30, 2022[29] - No purchases, sales, or redemptions of the company's listed securities were reported in the nine months ending September 30, 2023[4]

中 生 北 控 生 物科 技 股 份 有 限 公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION （於中華人民共和國註冊成立的股份有限公司） 8247 （股份代號： ） 截至二零二三年九月三十日止三個月及九個月 第三季度業績公佈 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供一個上市的 市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作 GEM GEM 出投資決定。 的較高風險及其他特色表示 較適合專業及其他老練投資者。 GEM GEM 由於 上市公司新興的性質所然，在 買賣的證券可能會較於聯交所主板買賣之證券 GEM 承受較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公佈的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 GEM GEM 本公佈乃遵照聯交所 《證券上市規則》（「 上市規則」） ...

Financial Performance - Biosino Bio-Technology reported a significant increase in revenue, achieving a total of RMB 200 million for the first half of 2023, representing a growth of 15% compared to the same period last year[19]. - The company's main business revenue for the six months ended June 30, 2023, was approximately RMB 139.1 million, a decrease of about 19.3% compared to RMB 172.4 million in the same period of 2022[32]. - Gross profit for the reporting period was approximately RMB 66.7 million, down about 4.8% from RMB 70.1 million in the same period last year, with a gross margin of approximately 48% compared to 41% in 2022[33]. - The company reported a loss of approximately RMB 8 million for the reporting period, compared to a profit of approximately RMB 4.7 million in the same period last year[37]. - The total comprehensive income for the six months ended June 30, 2023, was a loss of RMB 5,368,000, compared to a loss of RMB 7,956,000 for the same period in 2022[72]. - The operating profit for the six months ended June 30, 2023, was RMB 72,470,000, a decrease from RMB 102,381,000 in the same period of 2022, representing a decline of approximately 29.3%[89]. - The total tax expense for the six months ended June 30, 2023, was RMB 2,201,000, compared to RMB 2,440,000 in 2022, reflecting a decrease of approximately 9.8%[93]. - Basic earnings per share for the six months ended June 30, 2023, remained unchanged at RMB 0.50, consistent with the same period in 2022[94]. - The company did not declare an interim dividend for the six months ended June 30, 2023, which is the same as in 2022[98]. Research and Development - Research and development expenses increased by approximately 32.8% to RMB 16 million from RMB 12 million in the same period last year, with 49 Class II products and 3 Class III products completed for registration changes[36]. - The company is committed to developing new diagnostic technologies and products to meet the evolving needs of healthcare institutions[19]. - Future outlook indicates a strategic focus on expanding product lines and enhancing research and development efforts to maintain competitive advantage in the market[19]. - The company aims to leverage its strong ties with the Chinese Academy of Sciences to further enhance its research capabilities and product offerings[19]. Market Position and Strategy - The company expanded its distribution network, now covering over 600 distributors across more than 30 provinces and municipalities in China, enhancing its market reach[19]. - Biosino's diagnostic reagent products have gained widespread recognition, with the brand being awarded the "Beijing Famous Brand Product" title in 2002 and the "First Brand in User Satisfaction for Diagnostic Reagents in China" in 2005[19]. - The company plans to maintain quality advantages in traditional biochemical diagnostic products and increase market share through successful bidding in centralized procurement[40]. Financial Health and Assets - Biosino's financial health remains robust, with a solid balance sheet supporting ongoing investments in technology and market expansion initiatives[19]. - The net debt-to-equity ratio increased to 40% from 27% in the previous year, with total liabilities to total assets ratio remaining stable at 61%[45]. - As of June 30, 2023, the company had total non-current assets of RMB 208,403,000, slightly up from RMB 205,785,000 at the end of 2022[67]. - The company’s cash and cash equivalents decreased to RMB 54,777,000 as of June 30, 2023, down from RMB 77,349,000 at the end of 2022[67]. - The company’s inventory increased to RMB 65,012,000 as of June 30, 2023, compared to RMB 55,486,000 at the end of 2022[67]. - Total equity as of June 30, 2023, was RMB 226,151,000, down from RMB 234,107,000 as of December 31, 2022, indicating a decline of about 3.4%[69]. - The company reported a net cash decrease of RMB 22,572,000 for the six months ended June 30, 2023, compared to a decrease of RMB 8,347,000 in the same period of 2022[74]. Employee and Administrative Expenses - Total employee costs for the six months ended June 30, 2023, were approximately RMB 47,700,000, an increase of 15.8% from RMB 41,200,000 in the previous year[54]. - The increase in administrative expenses by approximately 20.6% to RMB 25.8 million was primarily due to rising employee costs[35]. - Sales and distribution expenses rose by approximately 7.9% to RMB 30.7 million, attributed to increased sales efforts[34]. - The total management compensation for the six months ended June 30, 2023, was RMB 3,145,000, a decrease from RMB 3,486,000 in 2022, reflecting a decline of about 9.8%[111]. Corporate Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements for the period[132]. - The company has complied with all corporate governance code provisions during the period, except for the internal audit function as per code provision D.2.5[133]. - The board has implemented measures to fulfill internal audit functions, including appointing external consultants for internal reviews[134]. - Following the resignation of an independent non-executive director, the company initially failed to meet the requirement of having at least three independent non-executive directors, which was rectified after a new appointment[137]. Shareholding and Securities - As of June 30, 2023, Mr. Wu Lebin holds 3,500,878 shares, representing 4.35% of the company's domestic shares and 2.42% of the total registered capital[116]. - Mr. Chen Peng holds 11,330,334 shares, accounting for 14.09% of the domestic shares and 7.83% of the total registered capital[116]. - Mr. Chen Zhengyong owns 10,000,000 shares, which is 12.43% of the domestic shares and 6.91% of the total registered capital[116]. - Beijing Pusai Asset Management Co., Ltd. directly holds 31,308,576 shares, representing 38.93% of the domestic shares and 21.64% of the total registered capital[118]. - Hong Kong Zhixin Investment Co., Ltd. holds 27,256,143 H shares, accounting for 42.40% of the H shares[118]. - Yunnan Shengneng Investment Partnership holds 10,939,314 domestic shares and 6,780,000 H shares, representing 13.60% and 10.55% of the respective categories[118]. - The company did not grant any rights to directors or supervisors to purchase shares or debt securities as of June 30, 2023[127]. - There were no purchases, sales, or redemptions of the company's listed securities by the company or its subsidiaries during the six months ending June 30, 2023[129]. - No directors, supervisors, or major shareholders held interests in any business that competes directly or indirectly with the company during the reporting period[128]. - The company has adopted the standards outlined in GEM Listing Rules 5.48 to 5.67 for the trading of securities by directors, with no known violations reported as of June 30, 2023[130].

中 生 北 控 生 物科 技 股 份 有 限 公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION （於中華人民共和國註冊成立的股份有限公司） 8247 （股份代號： ） 中期業績公佈 截至二零二三年六月三十日止三個月及六個月 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供一個上市的 市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作 GEM GEM 出投資決定。 的較高風險及其他特色表示 較適合專業及其他老練投資者。 GEM GEM 由於 上市公司新興的性質所然，在 買賣的證券可能會較於聯交所主板買賣之證券 GEM 承受較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公佈的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 GEM GEM 本公佈乃遵照 《證券上市規則》（「《 上市規則》」）的規定 ...